Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LADLY ABRAHAM

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1972537090
CMS profile
316423
Location
CONWAY, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$16,283.65

151 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LADLY ABRAHAM

NPI 1972537090 · CMS profile ID 316423

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

CONWAY, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972537090?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LADLY ABRAHAM, NPI 1972537090, CMS profile ID 316423. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972537090?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). LADLY ABRAHAM, NPI 1972537090, CMS profile ID 316423. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972537090?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
LADLY ABRAHAM, NPI 1972537090, CMS profile ID 316423, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1972537090?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

151 matching records · $16,283.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 151 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 151.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $14.3404/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829379985 CMS
Mallinckrodt Hospital Products Inc. $25.4004/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845341875 CMS
AstraZeneca Pharmaceuticals LP $12.0004/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829645423 CMS
GlaxoSmithKline, LLC. $13.8804/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802849239 CMS
GlaxoSmithKline, LLC. $9.7004/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802044097 CMS
GlaxoSmithKline, LLC. $15.2904/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802696804 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.7604/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763673958 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.8704/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763673960 CMS
Actelion Pharmaceuticals US, Inc. $23.1304/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788876981 CMS
AstraZeneca Pharmaceuticals LP $13.9303/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829281117 CMS
Electromed, Inc. $16.3503/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849609273 CMS
AstraZeneca Pharmaceuticals LP $850.0003/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829905571 CMS
Advanced Respiratory, Inc $21.2603/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853545515 CMS
AstraZeneca Pharmaceuticals LP $3,400.0003/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829754529 CMS
AstraZeneca Pharmaceuticals LP $2,550.0003/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830007725 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.1003/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763673962 CMS
Electromed, Inc. $1.9403/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849609265 CMS
GlaxoSmithKline, LLC. $16.7803/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802871457 CMS
Mallinckrodt Hospital Products Inc. $26.5103/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845341873 CMS
GlaxoSmithKline, LLC. $14.6003/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802619447 CMS
AstraZeneca Pharmaceuticals LP $97.1003/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829708659 CMS
AstraZeneca Pharmaceuticals LP $82.8803/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829753665 CMS
AstraZeneca Pharmaceuticals LP $66.5503/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830150769 CMS
GlaxoSmithKline, LLC. $16.4503/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802999329 CMS
AstraZeneca Pharmaceuticals LP $124.9503/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829958701 CMS
AstraZeneca Pharmaceuticals LP $771.1103/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830128227 CMS
GlaxoSmithKline, LLC. $16.4003/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801743889 CMS
Actelion Pharmaceuticals US, Inc. $12.1003/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788876985 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.1903/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763673964 CMS
AstraZeneca Pharmaceuticals LP $17.5003/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830009459 CMS
GlaxoSmithKline, LLC. $11.7203/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801742565 CMS
Sunovion Pharmaceuticals Inc. $24.1202/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821554873 CMS
AstraZeneca Pharmaceuticals LP $15.4602/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829986461 CMS
Mallinckrodt Hospital Products Inc. $10.8402/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845341871 CMS
GlaxoSmithKline, LLC. $13.7102/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802021339 CMS
GlaxoSmithKline, LLC. $16.4002/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801742243 CMS
Actelion Pharmaceuticals US, Inc. $14.5802/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788876979 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.3102/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763673966 CMS
GlaxoSmithKline, LLC. $10.8802/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802760259 CMS
Sunovion Pharmaceuticals Inc. $22.2001/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821596563 CMS
AstraZeneca Pharmaceuticals LP $14.6401/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829402793 CMS
GlaxoSmithKline, LLC. $14.4201/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801741109 CMS
Mallinckrodt Hospital Products Inc. $26.3901/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845341869 CMS
Advanced Respiratory, Inc $17.2001/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853545447 CMS
GlaxoSmithKline, LLC. $12.1401/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802676221 CMS
AstraZeneca Pharmaceuticals LP $15.7001/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829610959 CMS
GlaxoSmithKline, LLC. $13.9901/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802550803 CMS
Grifols USA, LLC $25.0501/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846746701 CMS
GlaxoSmithKline, LLC. $17.4601/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802402059 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $27.7901/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763673968 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $55,976.70 243
PY2020 $11,873.95 143
PY2021 $16,283.65 151
PY2022 $14,340.81 160
PY2023 $88,375.29 199
PY2024 $115,261.70 258
PY2025 $68,596.81 194

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $11,914.21 41
PY2023 Principal investigator $7,107.84 14
PY2022 Principal investigator $22,482.59 38
PY2021 Principal investigator $35,091.00 17
PY2019 Principal investigator $73,421.28 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Insmed, Inc. $137.28 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591622
Principal investigator 1 Insmed, Inc. $125.40 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591624
Principal investigator 1 Insmed, Inc. $125.40 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591626
Principal investigator 1 Insmed, Inc. $99.48 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591628
Principal investigator 1 Insmed, Inc. $51.60 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591630
Principal investigator 1 Insmed, Inc. $130.80 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591632
Principal investigator 1 Insmed, Inc. $51.60 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591634
Principal investigator 1 Insmed, Inc. $6.00 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597010
Principal investigator 1 Insmed, Inc. $2.64 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597012
Principal investigator 1 Insmed, Inc. $136.56 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597014
Principal investigator 1 Insmed, Inc. $195.60 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597016
Principal investigator 1 Insmed, Inc. $121.80 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597018
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597020
Principal investigator 1 Insmed, Inc. $137.28 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597022
Principal investigator 1 Insmed, Inc. $127.80 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597024
Principal investigator 1 Insmed, Inc. $51.60 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597026
Principal investigator 1 Insmed, Inc. $140.28 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597028
Principal investigator 1 Insmed, Inc. $109.68 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597030
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597032
Principal investigator 1 Insmed, Inc. $128.40 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597034
Principal investigator 1 Insmed, Inc. $99.48 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602374
Principal investigator 1 Insmed, Inc. $136.56 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602376
Principal investigator 1 Insmed, Inc. $195.60 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602378
Principal investigator 1 Insmed, Inc. $109.68 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602380
Principal investigator 1 Insmed, Inc. $99.48 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602382
Principal investigator 1 Insmed, Inc. $109.68 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602384
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602386
Principal investigator 1 Insmed, Inc. $121.80 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602388
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602390
Principal investigator 1 Insmed, Inc. $121.80 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602392
Principal investigator 1 Insmed, Inc. $136.56 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607764
Principal investigator 1 Insmed, Inc. $195.60 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607766
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607768
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607770
Principal investigator 1 Insmed, Inc. $127.80 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607772
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607774
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607776
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607778
Principal investigator 1 GlaxoSmithKline, LLC. $2,750.00 09/04/2024 Non-covered Recipient Entity
J AND L RESEARCH LLC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1127525076
Principal investigator 1 GlaxoSmithKline, LLC. $1,474.77 06/26/2024 Non-covered Recipient Entity
J AND L RESEARCH LLC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1127525078
Principal investigator 1 United Therapeutics Corporation $3,967.40 05/22/2024 Non-covered Recipient Entity
J&L Research LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149624097